Table 1.
Clinical characteristics of patients in RVMSP and RVAP groups
| Parameter | Value*
|
P | |
| RVMSP (n=45) | RVAP (n=47) | ||
| Age (year) | 70±15 | 75±10 | NS |
| Female | 22 (49%) | 15 (32%) | NS |
| The third degree AV-block | 25 | 26 | NS |
| Narrow QRS | 10 (22%) | 11 (23%) | NS |
| Wide QRS | 15 (33%) | 15 (32%) | NS |
| Left bundle branch block | 9 (20%) | 8 (17%) | NS |
| Right bundle branch block | 6 (13%) | 7 (15%) | NS |
| The second degree AV-block | 20 | 21 | NS |
| Narrow QRS | 10 (22%) | 11 (23%) | NS |
| Wide QRS | 10 (22%) | 10 (21%) | NS |
| Left bundle branch block | 6 (13%) | 5 (11%) | NS |
| Right bundle branch block | 4 (9%) | 5 (10%) | NS |
| Coronary heart disease | 14 (31%) | 19 (40%) | NS |
| Hypertension | 22 (49%) | 24 (51%) | NS |
| Diabetes | 13 (29%) | 10 (21%) | NS |
| Hyperlipidemia | 11 (24%) | 13 (28%) | NS |
| 35%<LVEF≤40% | 17 (38%) | 15 (32%) | NS |
| 40%<LVEF≤50% | 28 (62%) | 32 (68%) | NS |
| Pharmacologic therapy | |||
| ACE inhibitor or AT II blocker | 27 (60%) | 31 (69%) | NS |
| β-Blocker | 8 (18%) | 7 (15%) | NS |
| Loop diuretic | 6 (13%) | 9 (19%) | NS |
| Calcium channel blocker | 2 (4%) | 3 (6%) | NS |
Data are expressed as number (percentage), except for age (mean±SD). NS: not significant